MX2024006550A - Composiciones farmaceuticas para el tratamiento del dolor visceral. - Google Patents

Composiciones farmaceuticas para el tratamiento del dolor visceral.

Info

Publication number
MX2024006550A
MX2024006550A MX2024006550A MX2024006550A MX2024006550A MX 2024006550 A MX2024006550 A MX 2024006550A MX 2024006550 A MX2024006550 A MX 2024006550A MX 2024006550 A MX2024006550 A MX 2024006550A MX 2024006550 A MX2024006550 A MX 2024006550A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
treatment
visceral pain
compositions
pharmaceutical
Prior art date
Application number
MX2024006550A
Other languages
English (en)
Inventor
Michael Gerber
Carolyn Higgins
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of MX2024006550A publication Critical patent/MX2024006550A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/122Foams; Dry foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona péptidos, composiciones farmacéuticas, composiciones farmacéuticas líquidas; composiciones farmacéuticas de espuma rectal; y métodos para fabricar y usar las mismas, que pueden usarse para el tratamiento de una condición de dolor visceral (por ejemplo, dolor de vejiga asociado con cistitis intersticial/síndrome de dolor de vejiga (IC/BPS).
MX2024006550A 2021-11-29 2022-11-28 Composiciones farmaceuticas para el tratamiento del dolor visceral. MX2024006550A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163283731P 2021-11-29 2021-11-29
US202263382612P 2022-11-07 2022-11-07
PCT/US2022/080490 WO2023097309A1 (en) 2021-11-29 2022-11-28 Pharmaceutical compositions for the treatment of visceral pain

Publications (1)

Publication Number Publication Date
MX2024006550A true MX2024006550A (es) 2024-06-12

Family

ID=84689174

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006550A MX2024006550A (es) 2021-11-29 2022-11-28 Composiciones farmaceuticas para el tratamiento del dolor visceral.

Country Status (7)

Country Link
EP (1) EP4440595A1 (es)
KR (1) KR20240111797A (es)
AU (1) AU2022398687A1 (es)
CA (1) CA3238619A1 (es)
IL (1) IL313184A (es)
MX (1) MX2024006550A (es)
WO (1) WO2023097309A1 (es)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2968628A (en) 1958-10-17 1961-01-17 Shulton Inc Propellant composition
US3966090A (en) 1969-02-17 1976-06-29 Dart Industries Inc. Package for dispensing an antiseptic composition
US3714140A (en) 1971-03-16 1973-01-30 Squibb & Sons Inc Peptide synthesis
US3970219A (en) 1975-03-03 1976-07-20 Spitzer Joseph G Aerosol containers for foaming and delivering aerosols and process
US4411994A (en) 1978-06-08 1983-10-25 The President And Fellows Of Harvard College Protein synthesis
US4440320A (en) 1981-11-30 1984-04-03 Wernicke Steven A Foam dispensing apparatus
AU5963290A (en) 1989-06-30 1991-01-17 Massachusetts Institute Of Technology Inhibition of the n-end rule pathway in living cells
US5443369A (en) 1993-06-09 1995-08-22 Ingersoll-Rand Company Self-contained instrument and seal air system for a centrifugal compressor
NL1001366C2 (nl) 1995-10-06 1997-04-08 Airspray Int Bv Inrichting voor het afgeven van een luchtvloeistofmengsel, in het bijzonder schuim en daarvoor bestemde bedieningseenheid.
US6547162B1 (en) 1998-04-17 2003-04-15 Keltub B.V. Foam spraying device
US7504253B2 (en) 1999-06-11 2009-03-17 The Burnham Institute For Medical Research Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof
US7785832B2 (en) 2000-05-09 2010-08-31 HALLA Patent & Law Firm Method of protein synthesis
NL1016694C2 (nl) 2000-11-23 2002-05-24 Keltub B V Schuimvormingseenheid.
US6875438B2 (en) 2002-04-27 2005-04-05 Aventis Pharma Deutschland Gmbh Preparations for topical administration of substances having antiandrogenic activity
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
NL1022456C2 (nl) 2003-01-21 2004-07-22 Packaging Tech Holding Sa Drukverpakkingssysteem voor het op een in een drukverpakking opgenomen fluïdum aanbrengen van een werkdruk.
NL1022633C2 (nl) 2003-02-10 2004-08-12 Keltub B V Verbeterde schuimvormingseenheid.
NL1024350C2 (nl) 2003-09-23 2005-03-24 R & D Injector Ag Afgifte-eenheid voor geconcentreerd injecteren.
NL1028921C2 (nl) 2005-04-29 2006-11-01 Airspray Nv Afgifte-inrichting.
US7735692B2 (en) 2006-10-10 2010-06-15 Meadwestvaco Calmar, Inc. Rotating dispenser head with locking and venting closure connector for an air foaming pump dispenser
WO2008147536A1 (en) 2007-05-24 2008-12-04 President And Fellows For Harvard College Methods and compositions for enhancing proteasome activity
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
CN102686205A (zh) 2009-10-02 2012-09-19 弗艾米克斯有限公司 局部四环素组合物
US20120028286A1 (en) 2010-07-30 2012-02-02 Saller Charles F Method for evaluating the breakdown of proteins, polypeptides and peptides
US9429566B2 (en) 2011-09-28 2016-08-30 Université de Montréal Assay for inhibitors of CIP/KIP protein degradation
EP3288578B8 (en) * 2015-05-01 2023-03-29 Ironwood Pharmaceuticals, Inc. Compositions for colon cleansing and the treatment of gastrointestinal disorders
GB2554365B (en) 2016-09-22 2022-05-04 Aer Beatha Ltd Canister and valve
JP2020512292A (ja) * 2016-12-21 2020-04-23 アイアンウッド ファーマシューティカルズ インコーポレイテッド リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法

Also Published As

Publication number Publication date
WO2023097309A1 (en) 2023-06-01
IL313184A (en) 2024-07-01
CA3238619A1 (en) 2023-06-01
EP4440595A1 (en) 2024-10-09
KR20240111797A (ko) 2024-07-17
AU2022398687A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
EA201891946A1 (ru) Коагонисты глюкагона и glp-1 для лечения ожирения
MX2018013150A (es) Composición de hidrogel médico, e hidrogel médico, método de preparación del mismo y aplicación del mismo.
MX2019012464A (es) Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
PH12020551144A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2015015249A (es) Peptidos terapeuticos.
MX2021003187A (es) Inhibición de la peptidasa específica de ubiquitina 9x.
MX2020007876A (es) Terapia genica para la distrofia muscular de cinturas tipo 2c.
MX2024006288A (es) Dispositivos de suministro de farmacos in vivo y metodos para el suministro de farmacos.
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
MX2021007453A (es) Administracion perineural de resiniferatoxina para el tratamiento del dolor maladaptativo.
SG10201803112RA (en) Liquid treatment apparatus
MX2018001720A (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos.
PH12017501290A1 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
MX2019013096A (es) Peptidos para el tratamiento de diabetes.
ZA202211980B (en) Methods and treatment of trauma
MX2018016003A (es) Tratamiento combinado para lesiones neurológicas.
PH12021550122A1 (en) Solubilized apyrases, methods and use
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MX2020004058A (es) Inhibidores de d-aminoacido oxidasa y sus usos terapeuticos.
MX2024006550A (es) Composiciones farmaceuticas para el tratamiento del dolor visceral.
PH12021551138A1 (en) Application of chidamide in combination with r-chop, and drug combination
MX2019014867A (es) Metodo para tratar un efecto secundario de la inmunoterapia.
MX2022005376A (es) Moleculas de fusion del dominio extracelular (ecd) de la lectina 9 similar a inmunoglobulina que se une al acido sialico (siglec-9) y metodos de uso de las mismas.